The Pierre Fabre Group, the second-largest independent laboratory in France, employs about 9,300 people and achieved sales of 1.47 billion euros in 2004. More
• Address unmet medical needs in infectious diseases and cancer, using innovative therapeutic protein variants identified from a proprietary and original use of natural human genetic variability More
CollaGenex is developing dermatological applications of its proprietary IMPACS™ technology. Oracea™ (doxyxcycline, USP) 40 mg* was approved by the FDA on May 26, 2006. More
DFB, a specialty pharmaceutical company with expertise in liquid/semi-solid skin, soft tissue therapies, provides: branded products, outsourcing services, licensing opportunities More
BioVex : Developing a new class of vaccines to treat and prevent cancer - OncoVEX and ImmunoVEX, and a functional genomics platform for gene determination in the nervous system - NeuroVEX More
MedSource is a niche CRO focused on the Project Management and Monitoring of critical Phase I-IV studies in difficult therapeutics like Oncology, HIV, and Infectious disease. More
Focused on the Baltic region, Norameda UAB specializes in the sales, marketing and distribution of hospital and OTC products, it offers the best out-sourcing possibilities for pharmaceutical companies More
All rights reserved. Terms and Conditions | Contact us
